TransMedics Group (NASDAQ:TMDX) Trading 7.1% Higher – Here’s Why

Posted by Stanley Muller on May 20th, 2026

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) traded up 7.1% during trading on Monday . The company traded as high as $68.38 and last traded at $67.7150. 214,221 shares changed hands during trading, a decline of 80% from the average session volume of 1,057,757 shares. The stock had previously closed at $63.20.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Piper Sandler reduced their price target on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. TD Cowen cut their target price on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $135.00.

Read Our Latest Stock Report on TransMedics Group

TransMedics Group Price Performance

The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of 15.03 and a beta of 2.07. The stock’s 50 day simple moving average is $101.96 and its 200-day simple moving average is $121.85.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 EPS. On average, analysts expect that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

Insider Activity

In other news, Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $428,810.92. This represents a 29.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Anil P. Ranganath sold 864 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the transaction, the insider directly owned 13,091 shares in the company, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMDX. Vanguard Group Inc. grew its holdings in TransMedics Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after purchasing an additional 9,650 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of TransMedics Group by 11.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after buying an additional 113,817 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after buying an additional 322,353 shares during the period. Geode Capital Management LLC grew its stake in TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after buying an additional 2,903 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after buying an additional 223,409 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.